Discovery - University of Dundee - Online Publications

Library & Learning Centre

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

Standard

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. / Mohammed, Z. M. A.; McMillan, D. C.; Elsberger, B.; Going, J. J.; Orange, C.; Mallon, E.; Doughty, J. C.; Edwards, J.

In: British Journal of Cancer, Vol. 106, No. 2, 17.01.2012, p. 383-388.

Research output: Contribution to journalArticle

Harvard

Mohammed, ZMA, McMillan, DC, Elsberger, B, Going, JJ, Orange, C, Mallon, E, Doughty, JC & Edwards, J 2012, 'Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer' British Journal of Cancer, vol 106, no. 2, pp. 383-388., 10.1038/bjc.2011.569

APA

Mohammed, Z. M. A., McMillan, D. C., Elsberger, B., Going, J. J., Orange, C., Mallon, E., ... Edwards, J. (2012). Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 106(2), 383-388. 10.1038/bjc.2011.569

Vancouver

Mohammed ZMA, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E et al. Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer. 2012 Jan 17;106(2):383-388. Available from: 10.1038/bjc.2011.569

Author

Mohammed, Z. M. A.; McMillan, D. C.; Elsberger, B.; Going, J. J.; Orange, C.; Mallon, E.; Doughty, J. C.; Edwards, J. / Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.

In: British Journal of Cancer, Vol. 106, No. 2, 17.01.2012, p. 383-388.

Research output: Contribution to journalArticle

Bibtex - Download

@article{21ac1706300c4392a5ad618d92ae1a2f,
title = "Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer",
author = "Mohammed, {Z. M. A.} and McMillan, {D. C.} and B. Elsberger and Going, {J. J.} and C. Orange and E. Mallon and Doughty, {J. C.} and J. Edwards",
year = "2012",
doi = "10.1038/bjc.2011.569",
volume = "106",
number = "2",
pages = "383--388",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

A1 - Mohammed,Z. M. A.

A1 - McMillan,D. C.

A1 - Elsberger,B.

A1 - Going,J. J.

A1 - Orange,C.

A1 - Mallon,E.

A1 - Doughty,J. C.

A1 - Edwards,J.

AU - Mohammed,Z. M. A.

AU - McMillan,D. C.

AU - Elsberger,B.

AU - Going,J. J.

AU - Orange,C.

AU - Mallon,E.

AU - Doughty,J. C.

AU - Edwards,J.

PY - 2012/1/17

Y1 - 2012/1/17

N2 - <p>BACKGROUND: Immunohistochemistry of Ki-67 protein is widely used to assess tumour proliferation, and is an established prognostic factor in breast cancer. There is interest in automating the assessment of Ki-67 labelling index (LI) with possible benefits in handling increased workload, with improved accuracy and precision.</p><p>PATIENTS AND METHODS: Visual and automated assessment of Ki-67 LI and survival were examined in patients with primary operable invasive ductal breast cancer. Tissue microarrays (n=379 patients) immunostained for Ki-67 were scored visually and automatically with the Slidepath Tissue IA system.</p><p>RESULTS: Visual and automated Ki-67 LI were in excellent agreement (ICCC=0.96, P&lt;0.001). On univariate analysis, visual (P&lt;0.001) and automated Ki67 LI (P&lt;0.05) were associated with cancer-specific survival in patients with invasive ductal breast cancer overall and in patients who received endocrine therapy (Tamoxifen) (P&lt;0.01 for visual and P&lt;0.05 for automated scoring).</p><p>CONCLUSION: Automated assessment of Ki-67 LI would appear to be comparable to visual Ki-67 LI. However, automated Ki-67 LI assessment was inferior in predicting cancer survival in patients with breast cancer, including patients who received Tamoxifen. British Journal of Cancer (2012) 106, 383-388. doi:10.1038/bjc.2011.569 www.bjcancer.com Published online 3 January 2012 (C) 2012 Cancer Research UK</p>

AB - <p>BACKGROUND: Immunohistochemistry of Ki-67 protein is widely used to assess tumour proliferation, and is an established prognostic factor in breast cancer. There is interest in automating the assessment of Ki-67 labelling index (LI) with possible benefits in handling increased workload, with improved accuracy and precision.</p><p>PATIENTS AND METHODS: Visual and automated assessment of Ki-67 LI and survival were examined in patients with primary operable invasive ductal breast cancer. Tissue microarrays (n=379 patients) immunostained for Ki-67 were scored visually and automatically with the Slidepath Tissue IA system.</p><p>RESULTS: Visual and automated Ki-67 LI were in excellent agreement (ICCC=0.96, P&lt;0.001). On univariate analysis, visual (P&lt;0.001) and automated Ki67 LI (P&lt;0.05) were associated with cancer-specific survival in patients with invasive ductal breast cancer overall and in patients who received endocrine therapy (Tamoxifen) (P&lt;0.01 for visual and P&lt;0.05 for automated scoring).</p><p>CONCLUSION: Automated assessment of Ki-67 LI would appear to be comparable to visual Ki-67 LI. However, automated Ki-67 LI assessment was inferior in predicting cancer survival in patients with breast cancer, including patients who received Tamoxifen. British Journal of Cancer (2012) 106, 383-388. doi:10.1038/bjc.2011.569 www.bjcancer.com Published online 3 January 2012 (C) 2012 Cancer Research UK</p>

U2 - 10.1038/bjc.2011.569

DO - 10.1038/bjc.2011.569

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

VL - 106

SP - 383

EP - 388

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy